NCT04697940View on ClinicalTrials.gov

Decitabine-primed Tandem CD19/CD20 CAR T Cells Treatment in r/r B-NHL

PHASE1/PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

33

Participants

Timeline

Start Date

April 15, 2021

Primary Completion Date

May 31, 2025

Study Completion Date

September 1, 2026

Conditions
Relapsed and Refractory B-cell Non-Hodgkin's LymphomaDecitabine-primed Tandem CD19/CD20 CAR T Cells
Interventions
BIOLOGICAL

Decitabine-primed Tandem CAR19/20 engineered T cells

"Phase I dose escalation (3+3) : dose 1 (0.5 × 10\^6 cells per kg) dose 2 (2 × 10\^6 cells per kg) dose 3 (5 × 10\^6 cells per kg)~Phase II: Appropriate dose"

DRUG

Fludarabine

Intravenous fludarabine 25-30 mg/m\^2/day on days -5, -4, and -3.

DRUG

Cyclophosphamide

Intravenous cyclophosphamide 300-500 mg/m\^2/day on days -5, -4, and -3.

Trial Locations (1)

100853

Biotherapeutic Department of Chinese PLA General Hospital, Beijing

All Listed Sponsors
lead

Han weidong

OTHER